- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05971394
IBS Titan™ Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System Clinical Trial
A Prospective, Multicentre, Single Arm Clinical Trial to Assess the Safety and Effectiveness of Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™) in Treating Patients With Infrapopliteal Arterial Stenosis or Occlusive Disease
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ying Xia
- Phone Number: 0755 23221096
- Email: xiaying@lifetechmed.com
Study Locations
-
-
-
Florence, Italy
- Recruiting
- Azienda Ospedaliero Universitaria Careggi
-
Principal Investigator:
- Fabrizio Fanelli
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
• General criteria
- Subject between 18 and 85 years old.
- Subject who can understand the purpose of the trial, voluntarily participate in, and sign the informed consent form, and who are willing to participate until the 12 months follow-up.
- Subject has symptomatic Critical Limb Ischemia, Rutherford category 3-5.
Subject requires primary treatment of de novo infrapopliteal lesions.
• Angiographic criteria
- Target lesion stenosis ≥ 70% or occlusion in no more than two infrapopliteal arteries.
- The distal margin of the target lesion must be located ≥ 10 cm proximal to the proximal margin of the ankle mortise.
- The target lesion must be located in the proximal 2/3 of native infrapopliteal vessels, length is ≤ 200mm, with vessel diameter of 2.5-4 mm.
- Only two infrapopliteal vessels are allowed to be treated at the same time.
- A maximum of two stents can be deployed at one target vessel.
- There must be at least one unimpaired artery (< 30% stenosis) to the ankle.
Exclusion Criteria:
• General criteria:
- Severe renal insufficiency, hepatic dysfunction (Cr > 2 times normal limit or renal dialysis, ALT or AST > 5 times normal limit).
- Major amputation before index procedure or plan for major amputation.
- Any coagulation disorder.
- Lower extremity arteries surgery or thrombolytic therapy in the ipsilateral extremity in the past 6 weeks.
- Stroke within 3 months, or stroke with severe hemiplegia and aphasia sequelae more than 3 months before inclusion in the study.
- Acute myocardial infarction or acute ischemia within 30 days before inclusion in the study.
- Thromboangiitis obliterans (Buerger's disease).
- Any previous treatment with drug eluting balloon or drug eluting stent within 90 days before inclusion.
- Any surgery in target vessel before index procedure.
- Volume reduction operation in target vessel before inclusion.
- Subject known to be allergic to aspirin, heparin, clopidogrel, Polylactic acid, iron, zinc and its degradation products, contrast agents, sirolimus, etc., and those who cannot tolerate postoperative dual anti-platelet therapy.
- Subject with a history of iron overload or iron disorders related diseases, such as hereditary hemochromatosis, etc.
- Subject is currently participating in another clinical trial that has not yet completed its primary endpoint.
- Women of child-bearing potential not using an effective contraception; pregnant or lactating women.
- Subject is not suitable to participate in the trial as per investigators discretion.
Life expectancy ≤ 12 months as per investigators judgement.
• Angiographic criteria
- The inflow tract (including ipsilateral iliac artery, femoral artery, popliteal artery) has lumen stenosis >30% with or without intervention.
- The inflow tract (including ipsilateral iliac artery, femoral artery, popliteal artery) has > 150 mm stenosis or occlusion before treatment.
- Significant stenosis (≥50% stenosis) of the arterial outflow tract perfused by the target vessel.
- In-stent restenosis in any lower extremity artery.
- Thrombosis in target vessel, or acute thrombosis requiring thrombolysis and thrombectomy.
- Guide wire cannot pass target lesion.
- Angiography suggests intraoperative thromboendarterectomy, percutaneous transluminal rotational atherectomy or laser therapy are needed.
- Aneurysm of lower extremity artery in the ipsilateral leg.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IBS Titan
Subjects treated with IBS Titan™.Participants will be included in this arm.
|
Subjects in this arm will be treated with Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from Primary Efficacy Failure
Time Frame: 6 months
|
Defined as freedom from the composite of total occlusion of target lesion and clinically driven target lesion revascularization (CD-TLR), and freedom from major amputation.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major adverse event (MAE)
Time Frame: 1 month, 6 months, 12 months
|
Defined as a composite of all-cause mortality, CD-TLR and major amputation of target limb.
|
1 month, 6 months, 12 months
|
Rate of Device success
Time Frame: Immediately post-procedure
|
Stent level analysis, based on single stent.
Defined as the achievement of successful delivery, deployment of stent at the intended infrapopliteal target site(s) and successful withdrawal of the delivery catheter.
|
Immediately post-procedure
|
Rate of Technical success
Time Frame: Immediately post-procedure
|
Defined as the restoration of blood flow in the target vessel and angiogram indicates the residual stenosis <30%.
|
Immediately post-procedure
|
Rate of Procedural success
Time Frame: Immediately post-procedure
|
Defined as the combination of technical success, device success, and absence of procedural complications.
|
Immediately post-procedure
|
Incidence of Target lesion restenosis
Time Frame: 1 month, 6 months, 12 months
|
Defined as peak systolic velocity ratio (PSVR) >2.4 by DUS.
|
1 month, 6 months, 12 months
|
Change in ankle-brachial index (ABI) compared to baseline (before treatment)
Time Frame: 1 month, 6 months, 12 months
|
Change in Ankle Brachial Index (ABI) from pre-procedure.
Larger values mean a better outcome.
The ABI is the systolic pressure at the ankle, divided by the systolic pressure at the arm.
|
1 month, 6 months, 12 months
|
Change in Rutherford Category compared to baseline (before treatment)
Time Frame: 1 month, 6 months, 12 months
|
Categories and Clinical Description (higher scores mean a worse outcome): Category 0 = Asymptomatic, no hemodynamically significant occlusive disease, Category 1 = Mild claudication, Category 2 = Moderate claudication, Category 3 = Severe claudication, Category 4 = Ischemic rest pain, Category 5 = Minor tissue loss, non-healing ulcer, or focal gangrene with diffuse pedal ischemia, Category 6 = Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable. |
1 month, 6 months, 12 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Disease Attributes
- Atherosclerosis
- Peripheral Vascular Diseases
- Chronic Disease
- Peripheral Arterial Disease
- Ischemia
- Chronic Limb-Threatening Ischemia
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Sirolimus
Other Study ID Numbers
- BTK-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Critical Limb Ischemia
-
R3 Vascular Inc.RecruitingCritical Limb Ischemia | Critical Lower Limb Ischemia | Critical Limb-Threatening IschemiaAustralia
-
Fudan UniversityActive, not recruiting
-
University Health Network, TorontoUnknown
-
Changi General HospitalCompletedCritical Limb IschemiaSingapore
-
AnGes USA, Inc.TerminatedCritical Limb IschemiaUnited States, France, Belgium, Canada, Poland, Finland, Denmark, Netherlands, Hungary, Italy, Sweden
-
R-BioPusan National University HospitalCompletedCritical Limb IschemiaKorea, Republic of
-
Pharmicell Co., Ltd.Withdrawn
-
Lifecells, LLC.CompletedCritical Limb IschemiaUnited States
-
Neuromed IRCCSUnknown
Clinical Trials on Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)
-
Biotyx Medical (Shenzhen) Co., Ltd.RecruitingCritical Limb Ischemia (CLI)China
-
Biotyx Medical (Shenzhen) Co., Ltd.RecruitingPulmonary Artery StenosisChina
-
Lifetech Scientific (Shenzhen) Co., Ltd.Active, not recruiting
-
Biotyx Medical (Shenzhen) Co., Ltd.Active, not recruiting
-
Biotyx Medical (Shenzhen) Co., Ltd.Active, not recruitingCoronary Artery DiseaseChina
-
Lifetech Scientific (Shenzhen) Co., Ltd.RecruitingSingle Coronary Vessel DiseaseMalaysia
-
Meril Life Sciences Pvt. Ltd.UnknownCoronary Artery DiseaseMalaysia, Brazil, Indonesia, Macedonia, The Former Yugoslav Republic of
-
Meril Life Sciences Pvt. Ltd.Not yet recruitingCoronary Artery Disease
-
Meril Life Sciences Pvt. Ltd.Not yet recruiting
-
National Taiwan University HospitalUnknownImaging and Interventional Study for Erectile Dysfunction and Lower Urinary Tract Symptoms (PERFECT)Lower Urinary Tract Symptoms | Peripheral Arterial Disease | Erectile DysfunctionTaiwan